Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12387534 | 0.95 | SIGMAR1 (0.35) | SIGMAR1CYP1A2ERBB2FYNMAOA | |
| SCHEMBL15316834 | 0.89 | SIGMAR1 (0.30) | SIGMAR1CYP1A2ERBB2FYNMAOA | |
| SCHEMBL12387542 | 0.89 | — | — | |
| SCHEMBL15316862 | 0.88 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL10028179 | 0.87 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL13888820 | 0.86 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL13888821 | 0.86 | — | — | |
| SCHEMBL13888827 | 0.85 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL18969047 | 0.84 | SIGMAR1 (0.36) | SIGMAR1CYP1A2ERBB2FYNMAOA | |
| SCHEMBL18969059 | 0.83 | SIGMAR1 (0.35) | SIGMAR1CYP1A2ALDH1A1HSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329953-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-11 | — | — | US | disclosed |
| US-8329953-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-11 | — | — | US | disclosed |
| US-7990053-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| US-7990053-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| US-7919654-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-04-05 | — | — | US | disclosed |
| US-7919654-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-04-05 | — | — | US | disclosed |
| US-20110003985-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-01-06 | — | — | US | disclosed |
| US-20110003985-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-01-06 | — | — | US | disclosed |
| US-20100298607-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298607-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-11-25 | — | — | US | disclosed |
| US-20100289018-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| US-20100289018-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| US-7781579-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-08-24 | — | — | US | disclosed |
| US-7781579-B2 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-08-24 | — | — | US | disclosed |
| US-20070290610-A1 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2007-12-20 | — | — | US | disclosed |
| US-20070290610-A1 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298607-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | EML4, EED, LAGE3 | SIGMAR1 3914/4885CYP1A2 584/4885ERBB2 3260/4885 |
| US-20070290610-A1 | Cyclopentaphenanthrene-based compound and organic electroluminescent device using the same | EML4, EED, LAGE3 | SIGMAR1 3914/4885CYP1A2 584/4885ERBB2 3260/4885 |
| US-20110003985-A1 | CYCLOPENTAPHENANTHRENE-BASED COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | EML4, EED, LAGE3 | SIGMAR1 3914/4885CYP1A2 584/4885ERBB2 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.